CompletedNCT05617209

In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients

Studying Hemophilia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Principal Investigator
Brigitte Tardy, MD
Centre Hospitalier Universitaire de Saint Etienne
Intervention
thrombin generation measurement(other)
Enrollment
20 enrolled
Eligibility
12-65 years · MALE
Timeline
2021 – 2023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05617209 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials